Akkermansia Muciniphila Patent Landscape
Identifiers
Which organizations and claims shape current development around Akkermansia muciniphila?
Key organizations include Hainan Xunlong, filing multiple inactivated-AKK compositions for satiety, glucose control, liver protection, pediatric immunity, and sports performance; Danone, claiming pasteurized AKK for metabolic disorders; and Enterobiome, with a specific strain (EB-AMDK19) for atopic, respiratory, and hair loss applications. Academic and research institutions like Seoul National University, Korea Basic Science Institute, and Northeast Agricultural University contribute strain-specific claims for aerotolerance, cognitive function, and depression. Claims focus on defined deposit numbers, specific CFU ranges, and combination ratios with prebiotics, vitamins, minerals, and other probiotic strains, indicating a move toward proprietary, characterized strains.
How is Akkermansia muciniphila innovation changing in Food & Beverage?
Monthly patent filings by domain
Which technical problems do recent patents address with Akkermansia muciniphila?
Recent patents address metabolic, inflammatory, and age-related conditions, with a clear shift toward using inactivated or pasteurized forms to improve safety and stability. Specific targets include metabolic syndrome, diabetes, and weight loss (Danone, Guangzhou Zhiyi), satiety and postprandial glucose control (Hainan Xunlong), liver protection and hangover relief (Hainan Xunlong), and hepatic fibrosis (CJ Bioscience). The evidence also shows expansion into dermatological and neurological problems: photoaging, hair loss, atopic diseases, cognitive decline, and depression. A key technical problem is strain viability and handling, addressed by a hyper-aerotolerant strain (Seoul National University) and microencapsulation strategies.
How do recent patents change the role or application of Akkermansia muciniphila?
The ingredient's role is shifting from a live probiotic toward a versatile postbiotic or metabiotic platform. Multiple patents from Hainan Xunlong and Danone specifically claim inactivated, pasteurized, or metabolite-based compositions for satiety, glucose control, liver protection, and pediatric immunity, indicating a focus on non-viable formats for enhanced safety and stability. Concurrently, the application scope is broadening beyond gut and metabolic health into neurology (cognitive function, Alzheimer's, depression), dermatology (photoaging, hair loss), and allergy/asthma. This positions Akkermansia muciniphila as a multi-system bioactive ingredient rather than a conventional single-target probiotic.
How is Akkermansia muciniphila used in Food & Beverage patents?
Which Food & Beverage product categories feature Akkermansia muciniphila in recent patents?
Which product categories and formulation strategies emerge in recent work on Akkermansia muciniphila?
Emerging product categories span food, beverage, pharmaceutical, and cosmetic domains, including meal replacement powders, pediatric chewable gummies, sports performance compositions, hangover-relief products, and hair loss treatments. Formulation strategies emphasize combination with complementary actives: soluble dietary fibers for satiety, immune-enhancing ingredients like elderberry and zinc for pediatric products, hepatoprotective botanicals, hypoglycemic plant extracts, and other probiotic strains such as Bifidobacterium and Lactobacillus. A notable strategy is the use of inactivated or pasteurized forms at defined CFU-equivalent concentrations, alongside specific delivery formats like powders, granules, and chewable tablets, and strain-specific engineering for aerotolerance.
Where is the evidence-backed white space for further development of Akkermansia muciniphila?
Evidence-backed white space exists in combining inactivated Akkermansia muciniphila with specific, well-characterized active ingredients beyond the current scope. While patents cover combinations with fibers, botanicals, vitamins, and minerals for metabolic, liver, and immune targets, there is room for exploring synergistic blends with other postbiotics or novel prebiotics like human milk oligosaccharides, as seen in the depression patent. Additionally, the focus on pediatric and sports nutrition formats suggests white space in developing age-specific or lifestyle-specific delivery systems, such as gummies or ready-to-drink beverages, that leverage the safety profile of inactivated forms. Further strain engineering for aerotolerance and stability also remains an open area.